Former Roche employee questions marketing of oseltamivir to businessesBMJ 2010; 340 doi: http://dx.doi.org/10.1136/bmj.c2805 (Published 25 May 2010) Cite this as: BMJ 2010;340:c2805
- Andrew Jack
- 1Financial Times
A former employee of Roche has questioned the drug company’s sales practices for the antiviral drug oseltamivir (Tamiflu), as well as its efforts to maintain market share and tender for distributors for a broad range of products.
At Watford’s employment tribunal, John Miller claimed the UK subsidiary of the Swiss group had put pressure on sales staff to promote the blockbuster medicine osteltamivir to business continuity managers in companies keen to secure supplies of the scarce drug for private stockpiles, at a time of rising concerns about a flu pandemic.
His allegations came during his case to seek compensation for unfair dismissal, saying he was shifted internally and ultimately pushed out of the company because of his concerns over a series of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial